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The large chromosomal deletions frequently observed in cancer
genomes are often thought to arise as a “two-hit”mechanism in the
processof tumor-suppressorgene (TSG) inactivation.Usingamurine
model system of hepatocellular carcinoma (HCC) and in vivo RNAi,
we test an alternative hypothesis, that such deletions can arise from
selective pressure to attenuate the activity of multiple genes. By
targeting the mouse orthologs of genes frequently deleted on hu-
man 8p22 and adjacent regions, which are lost in approximately
half of several other major epithelial cancers, we provide evidence
suggesting that multiple genes on chromosome 8p can coopera-
tively inhibit tumorigenesis in mice, and that their cosuppression
can synergistically promote tumor growth. In addition, in human
HCC patients, the combined down-regulation of functionally vali-
dated 8p TSGs is associated with poor survival, in contrast to the
down-regulation of any individual gene. Our data imply that large
cancer-associated deletions can produce phenotypes distinct from
those arising through loss of a single TSG, and as such should be
considered and studied as distinct mutational events.
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Most cancer genomes contain large heterozygous deletions ofuncertain biological signiﬁcance. Early studies on the tu-
mor-suppressor genes (TSGs) RB and TP53 suggested that such
deletions can arise as a single mechanism for loss of heterozygosity
and, consequently, it is often assumed that they provide a “second-
hit” event to inactivate a single TSG (1). However, genomic
approaches have not conclusively identiﬁed a deﬁnitive TSG
within some cancer-associated deletions, raising the possibility
that they occur through genomic instability or selection for the
reduced activity of multiple genes. Even in chromosomal regions
where a bona ﬁde “two-hit” TSG has been identiﬁed, the large
deletions often associated with loss of heterozygosity reduce the
dosages of neighboring genes, which could in principle contribute
to tumorigenesis in a haploinsufﬁcient manner.
Large deletions encompassing regions of chromosome 8p are
very common in human tumors (2, 3) and often occur together with
8q gains encompassing MYC (4). Previously, we validated the 8p
geneDLC1, encoding a Rho GAP, as a TSG using a mouse model
of hepatocellular carcinoma (HCC), conﬁrming that its attenua-
tion can serve as a driving oncogenic event (3). Although DLC1 is
at an epicenter of deletions, these deletions are frequently much
larger and reduce the dosages of tens or hundreds of genes, often
encompassing the entire 8p22 cytoband and beyond (2, 5, 6). In-
deed, multiple candidate TSGs have been proposed in the region
(5–8). Here we explore the hypothesis that chromosome 8p dele-
tions arise owing to selection for the attenuation of multiple genes.
Results
Chromosome 8p Deletions Are Frequently Large and Co-Occur with 8q
Gains and 17p Loss. To better deﬁne regions affected by the 8p
deletions frequently occurring in human cancers, we determined
the extent of chromosome 8p deletions from cancer genome
datasets derived from array-based comparative genomic hybrid-
ization (aCGH) performed at Cold Spring Harbor Laboratory and
the Cancer Genome Atlas (TCGA) project, totaling 1411 primary
tumor samples and cell lines of HCC and breast, colon, and lung
cancers (Fig. 1A and Materials and Methods). According to these
data, approximately half of these tumors harbor heterozygous
deletions of human chromosome 8p, often encompassing a large
portion of or even the entire chromosome arm (Fig. 1A). Focusing
on 8p deletions in HCC, we noted that the most frequently deleted
region on 8p centered around the DLC1 gene (Fig. 1A), that in
HCC these deletions occur more frequently than those on chro-
mosome 17p encompassing TP53 (3). However, this chromosome
arm contains other candidate TSGs (5–8), and indeed, most dele-
tions encompass regions adjacent to DLC1, including the whole
8p22 cytoband or even the whole chromosome 8p arm (Fig. 1A).
To identify a relevant genetic context in which to study 8p loss,
we analyzed 197 primary HCCs (3, 9, 10) for copy number aber-
rations associated with 8p deletions (Fig. 1B). Ampliﬁcations of
chromosome 1q, 5p, 6p, and 8q (involving MYC) and losses in-
cluding TP53 on 17p were signiﬁcantly associated with 8p dele-
tions (Fig. 1B). In addition, unsupervised hierarchical linkage
clustering of 197 primary HCCs revealed that they fell within 12
groups, and that the 8p loss, 8q gain, and 17p loss cancers were
clustered mainly within one subgroup that represents ∼40% of all
HCCs (Fig. 1C). These data conﬁrm that genotypes involving
MYC overexpression and TP53 loss are a valid genetic context in
which to study candidate 8p TSGs.
Chromosome 8p Harbors Multiple Genes That Inhibit Tumorigenesis in
Mice. To identify TSGs located on 8p, we tested whether RNAi-
mediated suppression of various 8p genes would promote tu-
morigenesis in a mouse HCC model used previously for TSG
discovery (11). Initially focusing in an unbiased approach on the
8p22 region surrounding DLC1, we transduced pools of three
shRNAs individually targeting each mouse ortholog of all 21
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annotated 8p22 protein-coding genes into p53−/− liver progenitors
overexpressing Myc, thereby approximating a relevant genetic
context in humanHCCprogression. The resulting cell populations
were then assessed for their tumorigenic potential (Fig. 2A).
Whereas the parental cells transduced with control shRNA were
only weakly tumorigenic, cells harboring three of the 8p22 pools,
including one pool containing shRNAs targeting Dlc1, sub-
stantially promoted tumorigenesis above background (Fig. 2A).
The two other scoring shRNA pools targeted ﬁbrinogen-like 1
(Fgl1), a secreted protein of the ﬁbrinogen family that is a candi-
date TSG in human HCC (12), and vacuolar protein sorting 37
homolog a (Vps37a), a component of the ESCRT-I complex
mediating endosome sorting whose underexpression is associated
with poor survival in HCC patients (13).
Although chromosome 8p22 is at a deletion epicenter in HCC,
most 8p deletions span even larger regions (Fig. 1A). Thus, we
questioned whether yet other candidate TSGs lay in these adjacent
regions. Because there were toomany genes to test individually, we
used selection criteria based on high deletion frequency, under-
expression in human HCC, and potential tumor-suppressive
function, in accordance with the literature (Figs. S1 and S2 and
Table S1). We then repeated our experiments using shRNA pools
targeting the mouse orthologs of 19 genes from 8p23 and 8p21-
p11. Surprisingly, shRNAs targetingmany of these genes (14 of 19)
promoted tumorigenesis over background, although with sub-
stantial variability in tumor incidence and size (Fig. 2B and Table
S2). Five of these 14 genes demonstrated a statistically signiﬁcant
increase over background at the time of tumor harvest (Fig. 2B and
Table S2).
For further validation of the original candidates, we sub-
sequently tested the individual hairpins against the genes that
showed signiﬁcant tumor acceleration (i.e., Fgl1, Vps37a, Arh-
gef10, Bin3, Bnip3l, Scara5, and Trim35) plus one more (Fbxo25)
that, although not statistically signiﬁcant, yielded large tumors
compared with control in a subset of mice (Table S2). Multiple
shRNAs against Fgl1 or Vps37a that inhibited their corresponding
targets promoted tumorigenesis in mice (Fig. 2C and Fig. S3);
however, shRNA pools targeting Vps37a did not score consis-
tently in all experiments, suggesting that it is a weak tumor sup-
pressor or that its action is susceptible to subtle variations in
experimental conditions. For most hits examined (e.g., Fbxo25,
Fgl1, Trim35), the tumor-promoting effect of single shRNAs
correlated closely with the observed level of knockdown (Fig. 2C
and Fig. S3); however, this was not always the case (e.g.,Arhgef10),
perhaps indicating that some of the scoring shRNAs suppress
translation, or that more complete gene suppression impacts an
essential function, as we have described for Rad17 (14).
Fig. 1. Chromosome 8p deletion characteristics and co-occurring genomic aberrations. (A) Size and extent of chromosome 8p deletions (in blue) and
ampliﬁcations (in red) from individual HCCs, breast cancers, colon cancers, and lung adenocarcinomas based on aCGH data analysis (Materials and Methods).
The 8p22 cytoband is highlighted by a dashed line, with the organization of the 8p22 genes indicated on the right. (B) Chromosome 8p deletions co-occur
with genomic aberrations in HCC, including ampliﬁcations (red) of 1q, 5p, 6p, and 8q and deletions (blue) of 17p. Fisher’s exact test was used for statistical
calculations. (C) Unsupervised hierarchical clustering of genomic aberrations indicates 12 groups within the HCC dataset (n = 197). Occurrence of 8p deletion
(dark red), 8q ampliﬁcation (dark blue), and 17p deletion (dark orange) within the individual samples is highlighted below the dendrogram.
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In addition to Fgl1 and Vps37a, among the genes with tumor-
suppressive function validated in this way were the autophagy
regulator Bnip3l (15), the F-box protein encoding Fbxo25 (16),
and the ring ﬁnger, B-box, coiled-coil family gene Trim35 (17),
which has been recently reported as an HCC TSG candidate (18)
(Fig. 2C and Fig. S3). Also validated in these experiments were
the candidate TSGs Scara5, which negatively regulates focal
adhesion kinase signaling (19), and Arhgef10, previously impli-
cated in breast and urothelial carcinomas (5, 6) (Fig. S3). Our
screening assay was not without limitations, however; for exam-
ple, none of the single hairpins against Bin3 accelerated tu-
morigenesis. Although this might indicate that the screening
result was spurious, Bin3 shRNAs were also identiﬁed in a screen
for TSGs in lymphoma (20), and Bin3 knockout mice are tumor-
prone (21). Regardless, most hits identiﬁed in the screen were
validated in follow-up assays.
To control for the validity and speciﬁcity of our gene selection
criteria and screening approach, we repeated our experiments
using shRNA pools targeting randomly selected genes on chro-
mosome 8p, in contrast to the selection criteria (Figs. S1 and S2)
that we applied earlier to enrich for potential candidate genes. In
contrast to the high frequency at which candidates scored in our
initial assay (Fig. 2B), only 1 of 17 shRNA pools targeting ran-
domly selected chromosome 8p genes promoted tumorigenesis
above background (Fig. S4A). We also tested shRNA pools tar-
geting genes corresponding to human 5q31, a frequently deleted
region in acute myelogenous leukemia, but not in HCC. Only 1 of
these 23 targets scored in our assay, and suppression of this target
had only weak tumor-promoting effects (Fig. S4B). The speciﬁcity
of these results reinforces the biological relevance of our selection
criteria to enrich for genes with tumor-suppressive function in our
experimental system.
New TSGs Apparently Are Haploinsufﬁcient. Several of our obser-
vations imply that most of the validated genes that we identiﬁed
are relatively weak tumor suppressors that function through
a haploinsufﬁcient mode of action. First, none of the new TSGs
was as potent as the well-established TSGAPC (Fig. S3A). Second,
none of the scoring shRNAs tested was capable of complete
knockdown, and the resulting tumors retained residual mRNA
levels (Fig. S3B). Finally, and consistent with a previous report
analyzing mutations of 8p21 genes (22), exon sequencing and
methylation analysis of 13 matched tumor/normal HCC samples
indicated that although 9 of these tumors harbored 8p deletions,
neither DLC1 nor FGL1 showed evidence of somatic mutation or
promoter hypermethylation. Except for ARHGEF10, DLC1, and
SCARA5, none of these genes showed evidence of somatic point
mutations in public databases (Table S3), and none approached
the frequency of 8p deletion. Thus, it seems unlikely that any of
these biologically active TSGs are subject to a two-hit mutational
mechanism in HCC.
Individual 8p Genes Cooperate to Suppress Tumorigenesis. Our data
imply that the impact of 8p deletions goes beyond the effects of
DLC1 mutation or, for that matter, the attenuation of any in-
dividual gene. To determine whether the coattenuation ofmultiple
genes with tumor-suppressive function produced additive or
Fig. 2. Chromosome 8p deletions target multiple TSGs. (A and B) Average volume of tumors derived from s.c. injected p53−/−;Myc immortalized liver cells
infected with indicated shRNA pools. Error bars denote SD (n = 6). The Student t test comparing normalized samples at the time when mice were killed
relative to controls was used for statistical calculations. (C) Average tumor volumes of s.c. injected p53−/−;Myc immortalized liver cells infected with indicated
individual shRNAs. Error bars denote SD (n = 8). The Student t test comparing normalized samples at day 42 relative to control was used to calculate P values.
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cooperative effects, we examined the impact of coattenuating
DLC1—which is the only functionally validated 8p TSG in HCC
(3) and at a deletion epicenter (Fig. 1A)—and the best-validated
other TSGs from 8p22 (Fgl1) or adjacent regions (Fbxo25 and
Trim35). Indeed, coattenuation of the 8p22 gene Fgl1, the 8p21
gene Trim35, or the 8p23 gene Fbxo25withDlc1 by cotransduction
of shRNAvectors cooperated to promote tumor formation inmice
(Fig. 3A). Consistently, cosuppression of the three scoring 8p22
genes (Dlc1, Fgl1, and Vps37a) synergistically accelerated tumor
growth compared with single gene knockdown (Fig. 3 B and C). In
addition, copy number loss was highly correlated with DLC1,
TRIM35, and FBXO25 mRNA underexpression in primary HCC
and invasive breast cancer, which is consistent with their codele-
tion in most epithelial tumors (Fig. S5A andB). Collectively, these
data imply that coattenuation of physically linked TSGs can co-
operate during malignant transformation.
Down-Regulation of Multiple 8p TSGs Predicts Poor Survival. To
substantiate our ﬁndings in human cancer, we next asked whether
down-regulation of the validated individual 8p genes is associated
with survival outcome in human HCC. We analyzed gene ex-
pression data from a cohort of 195 HCC patients with available
survival data (23, 24). We found that although diminished ex-
pression of single genes or two genes together had no or only
moderate association with survival outcome (Fig. 4 A and B),
Fig. 3. Cooperativity of 8p TSGs. (A) Average tumor volumes (n = 4) of s.c. injected p53−/−;Myc immortalized liver cells infected or coinfected with indicated
shRNAs. Hairpins targeting Renilla served as controls. Error bars denote SD. Signiﬁcance was calculated using the Student t test comparing normalized
samples on day 35 relative to controls. (B) Average tumor volumes of s.c. injected p53−/−;Myc immortalized liver cells infected with indicated single shRNAs or
coinfected with all three shRNAs (Fgl1, Vps37a, and Dlc1). Error bars denote SD (n = 4). Of note, given the experimental organization, the individual con-
tribution of each TSGs in the triple-gene knockdown could not be determined. (C) Representative bioluminescence images from ﬁve mice with in situ liver
tumors from intrasplenically injected p53−/−;Myc liver progenitor cells infected with indicated single shRNAs or triple-infected with Fgl1, Vps37a, and Dlc1
shRNAs. Numbers shown indicate mean ± SD intensities of luciferase signals (n = 5).
Fig. 4. Association of survival and 8p gene expression in patients with HCC. (A and B) Survival curves comparing high and low expression of indicated single
genes (A) and combinations of two genes (B). (C) Survival association in patients with HCC (n = 192) for the entire cohort (all patients, black line) versus combined
low expression (red line) or high expression (blue line) of DLC1, FGL1, TRIM35, and FBXO25. Statistical testing was performed as described previously (24).
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diminished expression of all four validated cooperating TSGs
(DLC1, FGL1, FBXO25, and TRIM35) was signiﬁcantly corre-
lated with poor survival (Fig. 4C) and thus might predict more
aggressive disease progression. The reduced copy number status
of each of these four validated 8p genes was signiﬁcantly associ-
ated with survival (Fig. S6A), which is consistent with previous
reports examining the collective impact of 8p loss on survival (4,
25) and the fact each gene is invariably codeleted (Fig. S5A).
Taken together, these data underscore the fact that chromosome
8p contains multiple genes—likely more than have been identiﬁed
here—whose attenuated activity can promote tumorigenesis (Fig.
S6B). Although each gene contributes only a modest effect, their
combined attenuation may rival the impact of inactivating potent
TSGs, such as APC, RB, and TP53.
Discussion
Our data suggest that some recurrent cancer-associated dele-
tions reﬂect the selective advantage of simultaneously targeting
multiple two-hit and/or haploinsufﬁcient TSGs (1). Such a situ-
ation was described previously on chromosome 9p, although it
was attributed mainly to the unique organization of the INK4a/
ARF tumor-suppressor locus (26). Nonetheless, in other in vivo
RNAi screens, we identiﬁed additional situations in which mul-
tiple genes with tumor-suppressive functions could be validated
within the same genomic region (11, 20) and further analysis of
our HCC data revealed that large deletions surrounding well-
characterized TSG loci often encompass additional validated
and/or candidate TSGs (Fig. S7), supporting our idea that the
biology mediated by these large deletions goes beyond the effects
of individual genes.
The extent and complexity of chromosome 8p deletions suggests
that various candidate TSGs are targeted (5, 27, 28). Here we have
shown experimentally that cosuppression of linked 8p TSGs pro-
motes tumor formation more potently than any individual gene.
Our data suggest that along with the frequency 8p deletions oc-
curring in most epithelial tumors, 8p deletions speciﬁcally arise
from selective pressure to attenuate the activity of multiple genes
that may be separated by large distances, which explains the ob-
served extent of the deletions at the copy number level. Although
the possibility exists that genomic instability can fuel the losses that
we observed on chromosome 8p and in other genomic regions, our
data imply that these large events are selected for during tumor
progression because of the presence of a discrete number of linked
TSGs whose complete or partial attenuation individually may have
only a modest effect on tumor growth. This provides an important
nuance to the two prevailing views that a single gene in the region
is the “driver” or that aneuploidy (chromosome imbalance) per se
is crucial. The frequent large deletions on other chromosomes
(e.g., 3p, 5q, 9p, 17p) suggest that deletion of linked cancer genes
may play a broad role in cancer phenotypes.
None of the TSGs that we functionally identiﬁed showed evi-
dence of somatic inactivation of the remaining allele at a fre-
quency approaching that of their deletion, suggesting that these
genes do not ﬁt the canonical view of a TSG as deﬁned based on
studies ofRB1 andTP53. Nonetheless, our functional data suggest
that the expression of the 8p genes that we have identiﬁed is re-
duced in tumors with 8p deletions, and that the forced attenuation
of these genes promotes malignant growth in an in vivo experi-
mental system in a relevant cell type and genetic context. These
results raise the possibility that large-scale genomic lesions can act
through their effects on an opportunistic collection of linked genes
rather than through disruption of a single resident gene. Given the
extremely high frequency of these lesions in human cancers, this
hypothesis warrants further investigation.
Although this study has addressed the origin of large somatic
deletions occurring in human tumors, the notion that copy number
alterations may frequently target multiple drivers likely extends to
oncogenes located in common regions of ampliﬁcation as well.
Thus, work from our group and others has functionally validated
multiple drivers in common amplicons that in some cases co-
operate to produce more aggressive features and contribute to the
maintenance of disease (29–32). Collectively, these data raise the
possibility that methods integrating the complexity of copy num-
ber aberrations in tumors might be more accurate in predicting
and delineating tumor behavior compared with methods that fo-
cus on individual genes (33, 34).
Whether there is a biological rationale underlying the physical
linkage of some TSGs, and how their molecular function syner-
gizes, are not clear. However, the fact that these genes can co-
operate to suppress tumorigenesis implies that concomitant loss of
multiple genes may create unexpected vulnerabilities not easily
revealed through the study of single genes. Thus, codeletion of the
8p TSGs not only might create dependency on Rho signaling (3),
but also might deregulate autophagy (15), ubiquitination (16), and
other processes. Although the relevant biological effects remain to
be determined and are the focus of ongoing work, our results
demonstrate that cancer-associated deletions can create pheno-
types unique from those arising through loss of a single TSG, and
thus should be considered and studied as distinctmutational events.
Materials and Methods
Genomic Data Analysis. We analyzed the aCGH data produced using represen-
tational oligonucleotide microarray analysis for the frequency and size of dele-
tions in a series of human HCCs and breast, colon, and lung cancers available at
Cold Spring Harbor Laboratory (3, 11, 33). We used this method to study gene
dosage alterations in human HCC as described recently (33). Copy number
aberrations (CNAs) were visualized from the individual representational oligo-
nucleotide microarray analysis aCGH plots of the speciﬁc HCC samples using In-
tegratedGenomics Viewer software (Broad Institute; http://www.broadinstitute.
org/igv/home). In addition, available CNA from SNP6 arrays from the Cancer
Genome Atlas (http://cancergenome.nih.gov/) for HCC and breast, colon, and
lung adenocarcinomas were visualized using Integrated Genomics Viewer soft-
ware and analyzed for the occurrence of chromosome 8p deletion.
Co-occurrence of gene deletions and ampliﬁcations in HCC was performed
as described previously (34) by analyzing the aCGH dataset available at Cold
Spring Harbor Laboratory combined with two previously reported HCC
aCGH datasets (9, 10) publicly available at the Gene Expression Omnibus
(www.ncbi.nlm.nih.gov/geo; accession nos. GSE19399 and GSE9845), totaling
197 primary HCCs and 12 HCC cell lines. In brief, statistically signiﬁcant CNAs
in HCCs were analyzed for frequency and co-occurrence in individual sam-
ples, and Fisher’s exact test was used to calculate P values for co-occurrence
with chromosome 8p deletion.
Hierarchical clustering was performed by analyzing the combined HCC
dataset (see above) using Nexus Copy Number software 5.1 (BioDiscovery),
adding the signiﬁcant CNAs as individual factors for each sample andusing the
complete linkage hierarchical cluster tool to group the samples based on the
overall genomic aberrations. Subsequently, theannotated signiﬁcantCNAs for
individual samples were highlighted to visualize their occurrence within the
clusters. In addition, Nexus CopyNumber software 5.1 (BioDiscovery) was used
to determine deletion frequencies of the 8p genes outside of 8p22 (Table S1).
Gene expression analysis was performed using the Oncomine database
(www.oncomine.org), comparing multiple available HCC gene expression
datasets. Comparison of copy number aberrations and gene expression was
based on available TCGA datasets for HCC (53 samples) and invasive breast
cancer (320 samples). Cancer genome datasets and bioinformatic tools for
visualizing different parameters for analysis of genomic data are accessible
through the MSKCC cBio Core homepage (www.cbioportal.org).
shRNA Design, Cloning, and Vector Construction. miR30-shRNAs targeting
murine orthologs of human 8p genes, which show synteny to mouse chro-
mosomes 8A4-B2 (human 8p22), 8A1 (human 8p23), and 14D1 (8p21), were
designed as described previously (35). miR30 design shRNAs were PCR-ampli-
ﬁed from 97-mer oligonucleotides and cloned into MSCV-miR30-SV40-GFP or
MSCV-miR30-PGK-Puromycin-IRES-GFP retroviral vectors (36) and sequence-
veriﬁed. Myc was expressed using murine stem cell virus (MSCV) retroviral
vectors (11). For double-cooperativity experiments, shRNAs were subcloned
into MSCV-miR30-PGK-Neo-GFP or MSCV-miR30-PGK-Neo-mCherry.
Generation of Liver Carcinomas and Tumor Imaging. Isolation, culture, and
retroviral infection ofmurine hepatoblasts were described previously (32, 37).
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Liver progenitor cells from ED = 18 p53−/− fetal livers were immortalized
with MSCV-based retroviruses expressing Myc–IRES-GFP or Myc-IRES-lucif-
erase (11). To generate liver carcinomas, 2 × 106 ED = 13.5 liver progenitors
were retrovirally transduced and transplanted into livers of female C57/B6
(age 6–8 wk) by intrasplenic injection or injected s.c. into NCR nu/nu mice.
Hairpins targeting Renilla or an unspeciﬁc shRNA against human pRb were
used as controls. Validation of single hairpin experiments (Fig. S3) were
performed in newly derived liver progenitor cells from ED = 18 p53−/− fetal
livers immortalized with MSCV-based retroviruses expressing Myc.
For double-cooperativity experiments, liver carcinomas were generated
using liver progenitor cells immortalized with MSCV-based retroviruses
expressing Myc by retroviral cotransduction of the two shRNAs in MSCV-
based vectors containing either GFP or mCherry and subsequent s.c. injection
of 1 × 106 cells into NCR nu/nu mice. The following shRNAs were used:
shRen.713, shDlc1.3163, shTrim35.3034, shFbxo25.1551, and shFgl1.560. Tri-
ple-infection knockdown experiments were performed accordingly, except
that 3× control virus was used, and single shRNA virus was mixed with 2×
control virus to achieve comparable virus titers among the samples. Cells
were injected either s.c. or intrasplenically. The tumor volume of s.c. tumors
were calculated based on caliper measurements by the modiﬁed ellipsoidal
formula: 0.5 × (length × width2). To address tumor penetrance, the number
of tumors per injected site was counted (Table S2).
Intrasplenic injections and bioluminescence imaging for triple-knockdown
experiments were performed as described previously (37–39).
Gene Expression and Survival Analysis from Human Samples. The gene ex-
pressiondataof theHCCcohorthavebeenpublishedpreviously (23,24). Inbrief,
gene expression proﬁling was performed using the National Cancer Institute’s
Human Array-Ready Oligo Set microarray platform and Affymetrix GeneChip
HG-U133A2.0 arrays, respectively. Themicroarraydata are publicly available at
the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo; accession nos.
GSE5975 and GSE14520). The gene expression of DLC1 and FGL1 was obtained
from the Affymetrix arrays. TRIM35 and FBXO25 were not available on the
Affymetrix platform and therefore the gene expression data of the National
Cancer Institute’s Human Array-Ready Oligo Set microarray was used. For 195
patients, gene expression data were available on both microarray platforms,
and for 192 patients, survival data as well as cause of death were available.
Statistical analysis was performed as described previously (24).
Tissue Culture and Quantitative RT-PCR. Retroviral-mediated gene transfer
was performed using Phoenix packaging cells (provided by G. Nolan, Stanford
University, Stanford, CA) as described previously (40). RNA puriﬁcation and
quanrititive RT-PCR (qRT-PCR) were performed as described previously (3).
qRT-PCR reactions were done in triplicate using gene-speciﬁc primers. The
expression level of each gene was normalized to β-actin or GAPDH. qRT-PCR
primers were designed using PrimerBank (http://pga.mgh.harvard.edu/
primerbank/) and are listed in SI Text.
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